Doug Schenkel

Q: What is Doug Schenkel's success rate?

Doug Schenkel currently has a success rate of 100.

Q: What is the average return of Doug Schenkel's calls?

Their stock ratings have generated an average return of 75.34285609528906.

UBS | Healthcare

Doug Schenkel is an analyst from UBS specializing in the Healthcare sector. They are beginning to establish their track record, with 3 stock ratings so far. Their current stats show a success rate of 100.00% and an average return of 75.34%.

Doug Schenkel has only issued 3 ratings so far. While the sample size is small, their early calls show a success rate of 100.00% and an average return of 75.34%. Investors may find their initial activity in the Healthcare sector worth watching as they build a track record.

#121

Out of 4769

Total Ratings

+100.00%

Success Rate

+75.34%

Average Return

Recent Ratings Analysis

TMO

Buy

Sep 09, 2026

Target

$730.00

Current

$605.69

Performance

0.00%

Doug Schenkel rated TMO as Buy on Sep 09, 2026, setting a price target of 730. Shares have remained stable near 605.69, leaving the 730 target still in play.

CAI

Hold

Sep 09, 2026

Target

$28.00

Current

$24.03

Performance

0.00%

On Sep 09, 2026, CAI was given a Neutral rating by Doug Schenkel, with a target price of 28. Market indecision, reflected in sideways trading near 24.03, supported the cautious call.

ILMN

Buy

Sep 09, 2026

Target

$260.00

Current

$205.00

Performance

0.00%

ILMN received a Buy rating from Doug Schenkel on Sep 09, 2026, aiming for 260. Price action was muted, as shares hovered around 205 despite the bullish outlook.

WAT

Buy

Sep 09, 2026

Target

$490.00

Current

$404.81

Performance

0.00%

On Sep 09, 2026, Doug Schenkel published a Buy outlook on WAT, with a target of 490. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 404.81.

GRAL

Buy

Sep 09, 2026

Target

$105.00

Current

$77.48

Performance

0.00%

Doug Schenkel on Sep 09, 2026 assigned GRAL a Buy rating, with a price target of 105. The recommendation remains pending validation as shares consolidate around 77.48.

HTFL

Hold

Sep 09, 2026

Target

$55.00

Current

$46.67

Performance

0.00%

On Sep 09, 2026, Doug Schenkel reaffirmed HTFL with a Neutral rating, targeting 55. The neutral call matched muted market action of 0.00%.

TEM

Hold

Sep 09, 2026

Target

$70.00

Current

$61.28

Performance

0.00%

TEM was rated Neutral by Doug Schenkel on Sep 09, 2026, with a price objective of 70. Flat performance suggests the Hold view was reasonable.

TWST

Hold

Sep 09, 2026

Target

$144.00

Current

$125.52

Performance

0.00%

On Sep 09, 2026, Doug Schenkel initiated coverage on TWST with a Neutral rating and target of 144. The stock’s lack of movement around 125.52 aligned with a cautious approach.

RVTY

Hold

Sep 09, 2026

Target

$140.00

Current

$123.85

Performance

0.00%

Doug Schenkel issued a Neutral recommendation for RVTY on Sep 09, 2026, price target set at 140. The rating was appropriate for a consolidating market trading near 123.85.

BRKR

Buy

Dec 10, 2025

Target

$60.00

Current

$54.43

Performance

16.01%

On Dec 10, 2025, BRKR was evaluated by Doug Schenkel, who gave a Outperform rating and target of 60. This case illustrates how a timely bullish rating can translate into tangible gains of 16.01%.

GH

Buy

Sep 25, 2025

Target

$75.00

Current

$162.78

Performance

170.49%

Doug Schenkel rated GH as Outperform on Sep 25, 2025, setting a price target of 75. The call has proven timely, with shares rising 170.49% toward the price target of 75.

WST

Hold

Dec 13, 2024

Target

—

Current

$336.97

Performance

2.10%

On Dec 13, 2024, WST was given a Peer Perform rating by Doug Schenkel, with a target price of null. Market indecision, reflected in sideways trading near 336.97, supported the cautious call.

HOLX

Hold

Dec 13, 2024

Target

—

Current

$76.01

Performance

3.20%

HOLX received a Peer Perform rating from Doug Schenkel on Dec 13, 2024, aiming for null. Shares remained flat at 76.01, aligning with the neutral rating.

STVN

Buy

Dec 13, 2024

Target

$28.00

Current

$20.24

Performance

-13.17%

On Dec 13, 2024, Doug Schenkel published a Outperform outlook on STVN, with a target of 28. Market action contradicted the Buy thesis, as shares slipped to 20.24.

QGEN

Buy

Jun 27, 2024

Target

$50.00

Current

$42.50

Performance

-4.48%

Doug Schenkel on Jun 27, 2024 assigned QGEN a Outperform rating, with a price target of 50. The recommendation remains pending validation as shares consolidate around 42.5.

A

Hold

Jun 27, 2024

Target

—

Current

$144.78

Performance

10.69%

On Jun 27, 2024, Doug Schenkel reaffirmed A with a Peer Perform rating, targeting null. Market strength beyond 144.78 went further than the conservative outlook suggested.

TXG

Hold

Jun 27, 2024

Target

—

Current

$67.29

Performance

238.99%

TXG was rated Peer Perform by Doug Schenkel on Jun 27, 2024, with a price objective of null. Despite caution, upside momentum rewarded risk-takers with gains to 67.29.

Frequency Asked Questions

Who is Doug Schenkel?

Doug Schenkel is an analyst from UBS specializing in the Healthcare sector.

What is Doug Schenkel's success rate?

Doug Schenkel currently has a success rate of +100.00%.

How many ratings has Doug Schenkel issued?

Doug Schenkel has issued 3 stock ratings so far.

What is the average return of Doug Schenkel's calls?

Their stock ratings have generated an average return of +75.34%.

What is Doug Schenkel's ranking?

Doug Schenkel is ranked #121 out of 4769 analysts.

What types of ratings does Doug Schenkel give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Doug Schenkel?

You can follow Doug Schenkel by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Doug Schenkel?

Their latest rating was a Buy on TMO issued on 2026-09-09.